Prognosis and immunotherapy response prediction based on M2 macrophage-related genes in colon cancer
-
Published:2024-01-25
Issue:2
Volume:150
Page:
-
ISSN:1432-1335
-
Container-title:Journal of Cancer Research and Clinical Oncology
-
language:en
-
Short-container-title:J Cancer Res Clin Oncol
Author:
Xu Xiaochen,Zhang Xinwen,Kou Ruilong,Liu Yihao,Chen Siqi,Li Zuguo,Jian Zhiyuan,wang Zhenran
Abstract
Abstract
Background
M2 macrophage were revealed to play a crucial role in immune evasion and immunotherapies. This study aims to explore the potential significance of M2 macrophage-related genes in colon adenocarcinoma (COAD) by analysizing the transcriptome data in a comprehensive way.
Methods
We collected RNA-sequencing (RNA-seq) data of COAD from The Cancer Genome Atlas (TCGA) and Gene Expression Ominibus (GEO) databases. We calculated the immune infiltration scores of every sample using CIBERSORT algorithm. Through weighted gene co-expression network analysis (WGCNA), we picked out M2 macrophage-related genes. With these genes we screened out prognosis related genes which were utilized to construct a signature to assess the prognosis of patients. To extend the potential application of the signature, we also calculated the correlations with immune infiltration. Finally, we applied techniques such as quantitative reverse transcription polymerase chain reaction (qRT–PCR) and immunoblotting (Western Blotting) to validate the RNF32 gene in cellular in vitro assays.
Results
Seven M2 macrophage-related genes signature was constructed, which was an excellent prognostic predictor in two independent groups. The high-risk group showed lower immune infiltration and poorer response to immunotherapies than those of the low-risk group. The cell vitro experiments showed that the expression level of RNF32 was upregulated in colon cancer cell lines compared with normal cell lines. Moreover, we found that RNF32 may promote the proliferation, migration and invasion of cancer cells in vitro by inhibiting apoptosis.
Conclusion
A novel M2 macrophage-related gene signature affects the prognosis and immune characteristics of colon cancer.
Funder
Innovation Project of Guangxi Graduate Education China's National Natural Science Foundation
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Cao L, Che X, Qiu X, Li Z, Yang B, Wang S, Hou K, Fan Y, Qu X, Liu Y (2019) M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer. [Journal Article]. Cancer Manag Res 11:6125–6138. https://doi.org/10.2147/CMAR.S199832 2. Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z (2017) Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. [Journal Article; Research Support, Non-U.S. Gov't]. Cell Rep 18(1): 248–262. https://doi.org/10.1016/j.celrep.2016.12.019 3. Chen Y, Zhang S, Wang Q, Zhang X (2017) Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein. [Journal Article]. J Hematol Oncol, 10(1): 36. https://doi.org/10.1186/s13045-017-0408-0 4. Choo YW, Kang M, Kim HY, Han J, Kang S, Lee JR, Jeong GJ, Kwon SP, Song SY, Go S, Jung M, Hong J, Kim BS (2018) M1 Macrophage-derived nanovesicles potentiate the anticancer efficacy of immune checkpoint inhibitors. [Journal Article; Research Support, Non-U.S. Gov't]. ACS Nano, 12(9): 8977–8993. https://doi.org/10.1021/acsnano.8b02446 5. De Henau O, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH, Budhu S, Ghosh A, Pink M, Tchaicha J, Douglas M, Tibbitts T, Sharma S, Proctor J, Kosmider N, White K, Stern H, Soglia J, Adams J, Palombella VJ, McGovern K, Kutok JL, Wolchok JD, Merghoub T (2016) Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells. Nature 539(7629):443–447. https://doi.org/10.1038/nature20554
|
|